LEO Pharma & Egypt’s Minapharm expand a longstanding strategic manufacturing partnership of three decades. The successful long-term brands Fucidin® and Fucicort® account for dominant market shares in their categories. The new agreement further adds commercialization of a full portfolio of innovative dermatologic therapeutics for treatment of psoriasis and atopic dermatitis to fulfill unmet medical needs of patients across Egypt, a country that remains among the largest consumers of pharmaceuticals in the Middle East and Africa.
This agreement is in line with LEO Pharma’s strategy of building a simple yet competitive organizational model that extends to Minapharm’s advanced manufacturing capabilities for further providing high-quality, innovative solutions.
The two companies seek to solidify brand presence and improve patient health outcomes in the region. Minapharm’s experienced teams and broad distribution networks will ensure LEO Pharma products reach modern trade, traditional trade, hospitals, clinics, and other medical channels, reinforcing their accessibility by all patients in need across the country.
“Signing this agreement is a pinnacle of collaboration following three decades of manufacturing LEO’s flagship dermatology products. It further expands the business with a portfolio of novel skin therapeutics and unfolds future business opportunities.” says Dina Soliman, Director of Strategic Operations and Business Development of Minapharm Pharmaceuticals.